Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 12/20 | 0.44 |
| ▸ | MMEL1 | Q495T6 | 6/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968716 | 0.91 | MME (0.38) | MMEMMEL1CTSA | |
| SCHEMBL2394161 | 0.89 | MMEL1 (0.42) | MMEMMEL1CTSAAGTR1AGTR2 | |
| SCHEMBL2395518 | 0.87 | PYGL (0.36) | MME | |
| SCHEMBL2390811 | 0.81 | CTSA (0.37) | MMEMMEL1CTSA | |
| SCHEMBL653296 | 0.79 | MME (0.44) | MMEMMEL1CTSA | |
| SCHEMBL994887 | 0.79 | MME (0.44) | MMEMMEL1CTSA | |
| SCHEMBL1970764 | 0.78 | PYGL (0.35) | MME | |
| SCHEMBL2393584 | 0.76 | MMEL1 (0.45) | MMEMMEL1CTSAAGTR1 | |
| SCHEMBL2390362 | 0.75 | AGTR1 (0.38) | MMEAGTR1 | |
| SCHEMBL3264622 | 0.73 | AGTR1 (0.40) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865755-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8338418-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120214849-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8080572-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110230525-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7863309-B2 | imidazole or triazole derivatives such as 4-[4-((R)-1-Benzyl-2-hydroxycarbamoylethylcarbamoyl)-2-butylimidazol-1-ylmethyl]benzoic acid methyl ester, used for treating congestive heart failure or as hypotensive agents | THERAVANCE, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100022599-A1 | imidazole or triazole derivatives such as 4-[4-((R)-1-Benzyl-2-hydroxycarbamoylethylcarbamoyl)-2-butylimidazol-1-ylmethyl]benzoic acid methyl ester, used for treating congestive heart failure or as hypotensive agents | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210874-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | MME 6/4885MMEL1 776/4885CTSA 438/4885 |
| US-20110230525-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | MME 6/4885MMEL1 776/4885CTSA 438/4885 |
| US-20100022599-A1 | imidazole or triazole derivatives such as 4-[4-((R)-1-Benzyl-2-hydroxycarbamoylethylcarbamoyl)-2-butylimidazol-1-ylmethyl]benzoic acid methyl ester, used for treating congestive heart failure or as hypotensive agents | AGTR1, REN, AGTR2 | MME 4/4885MMEL1 263/4885CTSA 1413/4885 |
| US-20120214849-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | MME 6/4885MMEL1 776/4885CTSA 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.